AbbVie Inc. $ABBV Shares Acquired by ABN AMRO Bank N.V.

ABN AMRO Bank N.V. increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 933,075 shares of the company’s stock after buying an additional 9,087 shares during the quarter. AbbVie comprises approximately 2.1% of ABN AMRO Bank N.V.’s holdings, making the stock its 17th largest position. ABN AMRO Bank N.V.’s holdings in AbbVie were worth $215,206,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ABBV. Altrius Capital Management Inc boosted its holdings in shares of AbbVie by 0.4% during the third quarter. Altrius Capital Management Inc now owns 25,850 shares of the company’s stock valued at $5,985,000 after acquiring an additional 99 shares during the period. Flagship Harbor Advisors LLC lifted its position in AbbVie by 0.7% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 33,313 shares of the company’s stock valued at $7,713,000 after purchasing an additional 222 shares during the last quarter. HighPoint Advisor Group LLC boosted its stake in AbbVie by 1.4% during the 3rd quarter. HighPoint Advisor Group LLC now owns 182,897 shares of the company’s stock valued at $42,348,000 after purchasing an additional 2,527 shares during the period. HORAN Wealth LLC grew its position in AbbVie by 51.8% in the 3rd quarter. HORAN Wealth LLC now owns 24,350 shares of the company’s stock worth $5,638,000 after purchasing an additional 8,313 shares during the last quarter. Finally, Horizon Investment Services LLC grew its position in AbbVie by 13.6% in the 3rd quarter. Horizon Investment Services LLC now owns 1,342 shares of the company’s stock worth $311,000 after purchasing an additional 161 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised FY outlook — AbbVie reported Q4 adjusted EPS of $2.71 and revenue of $16.62B, topping estimates; management gave 2026 adjusted EPS guidance of $14.37–$14.57, above consensus, supporting the view of durable profit growth. Article Title
• Positive Sentiment: Immunology momentum — Strong demand for Skyrizi (+32% Y/Y) and Rinvoq (+29% Y/Y) drove the beat and are cited by management as the engine of revenue growth, partially offsetting Humira declines. Analysts point to continued upside from these franchises. Article Title
• Positive Sentiment: Rinvoq label expansion in progress — AbbVie submitted regulatory applications for Rinvoq (upadacitinib) in vitiligo (FDA/EMA), a meaningful new indication if approved that could support longer?term growth. Article Title
• Neutral Sentiment: Analyst positioning mixed — Some firms (e.g., Evercore) kept bullish ratings citing immunology strength and neurology upside, while others are pausing to re?assess targets; this is keeping trading volatile. Article Title
• Negative Sentiment: Q1 guidance missed expectations — AbbVie issued Q1 2026 EPS guidance of $2.97–$3.01 versus a ~ $3.11 consensus, and revenue guidance came in below forecasts, prompting concern about near?term growth momentum. (Company guidance update)
• Negative Sentiment: Segment weakness and diversification worries — Aesthetics (Botox/Cosmetics) and parts of oncology showed declines and some reports flag that growth is concentrated in immunology; commentators warn the company may lean on M&A/IPR&D to sustain growth. Article Title
• Negative Sentiment: Investor skepticism on Rinvoq contribution and valuation questions — Some coverage highlights that Rinvoq’s role vs. expectations (and valuation implications for the company) remains under scrutiny despite the drug’s growth. Article Title

AbbVie Price Performance

Shares of ABBV opened at $217.04 on Thursday. The firm’s 50 day moving average is $223.99 and its 200-day moving average is $219.14. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The stock has a market capitalization of $383.59 billion, a P/E ratio of 164.42, a P/E/G ratio of 0.93 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period last year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Evercore ISI reaffirmed an “outperform” rating and set a $228.00 price target on shares of AbbVie in a report on Wednesday. Berenberg Bank set a $275.00 price target on AbbVie in a report on Tuesday, January 20th. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research note on Tuesday, November 4th. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Finally, Morgan Stanley raised their target price on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $251.50.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.